Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis

  • Binit Vaidya National Center for Rheumatic Diseases, Kathmandu, Nepal
  • Bhojraj Adhikari Bharatpur Hospital, Bharatpur, Chitwan, Nepal
  • Manisha Bhochhibhoya National Center for Rheumatic Diseases, Kathmandu, Nepal
  • Shweta Nakarmi National Center for Rheumatic Diseases, Kathmandu, Nepal

Abstract

Drug-induced arthritis is not an uncommon scenario. DPP-4 inhibitors could potentially cause adverse-events mediated by cytokine-induced inflammation leading to arthritis. The activity of the DPP-4 enzyme could be inversely related to the development of rheumatoid arthritis, explaining the increased inflammatory activity with its inhibition by a drug. We discuss a 72-year-old gentleman with twenty-three years of history of type 2 diabetes mellitus, who after 6 years of treatment with a DPP-4 inhibitor, developed features of inflammatory arthritis and fulfilled the criteria for seronegative rheumatoid; which eventually subsided after stopping the drug.
Keywords: DDP-4 inhibitor; diabetes mellitus; Nepal; rheumatoid arthritis; seronegative

Published
2021-12-15
How to Cite
VaidyaB., AdhikariB., BhochhibhoyaM., & NakarmiS. (2021). Late Onset Dipeptidyl Peptidase -4 Inhibitor Associated Seronegative Rheumatoid Arthritis. Journal of Nepal Health Research Council, 19(03), 644-646. https://doi.org/10.33314/jnhrc.v19i3.3433